1-3 of 3
Philippe Rousselot
Close
Sort by
Journal Articles

Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML

Clinical Trials & Observations
Stéphane de Botton, Thomas Cluzeau, Carlos Vigil, Rachel J. Cook, Philippe Rousselot, David A. Rizzieri, Jane L. Liesveld, Pierre Fenaux, Thorsten Braun, Anne Banos, Joseph G. Jurcic, Mikkael A. Sekeres, Michael R. Savona, Gail J. Roboz, Dale Bixby, Kate Madigan, Angela Volkert, Kristin Stephens, Qing Kang-Fortner, Kristen Baker, Sofia Paul, Michael McKeown, John Carulli, Matthew Eaton, Graeme Hodgson, Christopher Fiore, Michael J. Kelly, David A. Roth, Eytan M. Stein
Journal: Blood Advances
Blood Adv (2023) 7 (9): 1858–1870.
https://doi.org/10.1182/bloodadvances.2022008806
Published: 2023
Includes: Supplemental data
Journal Articles

Early detection of WT1 measurable residual disease identifies high-risk patients, independent of transplantation in AML

Clinical Trials & Observations
Juliette Lambert, Jerome Lambert, Xavier Thomas, Alice Marceau-Renaut, Jean-Baptiste Micol, Aline Renneville, Emmanuelle Clappier, Sandrine Hayette, Christian Récher, Emmanuel Raffoux, Arnaud Pigneux, Celine Berthon, Christine Terré, Karine Celli-Lebras, Sylvie Castaigne, Nicolas Boissel, Philippe Rousselot, Claude Preudhomme, Hervé Dombret, Nicolas Duployez
Journal: Blood Advances
Blood Adv (2021) 5 (23): 5258–5268.
https://doi.org/10.1182/bloodadvances.2021004322
Published: 2021
Includes: Supplemental data
Journal Articles

Late molecular recurrences in patients with chronic myeloid leukemia experiencing treatment-free remission

Clinical Trials & Observations
Philippe Rousselot, Clémence Loiseau, Marc Delord, Jean Michel Cayuela, Marc Spentchian
Journal: Blood Advances
Blood Adv (2020) 4 (13): 3034–3040.
https://doi.org/10.1182/bloodadvances.2020001772
Published: 2020
Includes: Supplemental data